发布求助
文献互助 智能选刊 最新文献

Therapeutic delivery最新文献

筛选
英文 中文
Industry updates in the field of therapeutic delivery in June 2024. 2024 年 6 月治疗给药领域的行业动态。
IF 3
Therapeutic delivery Pub Date : 2024-10-11 DOI: 10.1080/20415990.2024.2408214
Mengistie Diress, Armin Mooranian, Hani Al-Salami
{"title":"Industry updates in the field of therapeutic delivery in June 2024.","authors":"Mengistie Diress, Armin Mooranian, Hani Al-Salami","doi":"10.1080/20415990.2024.2408214","DOIUrl":"https://doi.org/10.1080/20415990.2024.2408214","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies. 依托度酸在骨关节炎中的应用：给药挑战、局部纳米治疗策略和潜在的协同作用。
IF 3
Therapeutic delivery Pub Date : 2024-09-30 DOI: 10.1080/20415990.2024.2405456
Pavani Gaddala, Shalki Choudhary, Sheshank Sethi, Vaskuri Gs Sainaga Jyothi, Chantibabu Katta, Deepankar Bahuguna, Pankaj Kumar Singh, Manisha Pandey, Jitender Madan
{"title":"Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies.","authors":"Pavani Gaddala, Shalki Choudhary, Sheshank Sethi, Vaskuri Gs Sainaga Jyothi, Chantibabu Katta, Deepankar Bahuguna, Pankaj Kumar Singh, Manisha Pandey, Jitender Madan","doi":"10.1080/20415990.2024.2405456","DOIUrl":"https://doi.org/10.1080/20415990.2024.2405456","url":null,"abstract":"<p><p>Osteoarthritis (OSA) is a prevalent joint disorder characterized by losing articular cartilage, primarily affecting the hip, knee and spine joints. The impact of OSA offers a major challenge to health systems globally. Therapeutic approaches encompass surgical interventions, non-pharmacological therapies (exercise, rehabilitation, behavioral interventions) and pharmacological treatments. Inflammatory processes within OSA joints are regulated by pro-inflammatory and anti-inflammatory cytokines. Etodolac, a COX-2-selective inhibitor, is the gold standard for OSA management and uniquely does not inhibit gastric prostaglandins. This comprehensive review offers insights into OSA's pathophysiology, genetic factors and biological determinants influencing disease progression. Emphasis is placed on the pivotal role of etodolac in OSA management, supported by both preclinical and clinical evidences in topical drug delivery. Notably, <i>in</i>-<i>silico</i> docking studies suggested potential synergies between etodolac and baicalein, considering ADAMTS-4, COX-2, MMP-3 and MMP-13 as essential therapeutic targets. Integration of artificial neural network (ANN) techniques with nanotechnology approaches emerges as a promising strategy for optimizing and personalizing topical etodolac delivery. Furthermore, the synergistic potential of etodolac and baicalein warrants in-depth exploration. Hence, by embracing cutting-edge technologies like ANN and nanomedicine, the optimization of topical etodolac delivery could guide a new era of OSA treatment.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-19"},"PeriodicalIF":3.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review. 神经退行性疾病的纳米技术驱动疗法：综述。
IF 3
Therapeutic delivery Pub Date : 2024-09-19 DOI: 10.1080/20415990.2024.2401307
Jessica López-Espinosa, Peter Park, Morgan Holcomb, Biana Godin, Sonia Villapol
{"title":"Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review.","authors":"Jessica López-Espinosa, Peter Park, Morgan Holcomb, Biana Godin, Sonia Villapol","doi":"10.1080/20415990.2024.2401307","DOIUrl":"https://doi.org/10.1080/20415990.2024.2401307","url":null,"abstract":"<p><p>Neurological diseases, characterized by neuroinflammation and neurodegeneration, impose a significant global burden, contributing to substantial morbidity, disability and mortality. A common feature of these disorders, including stroke, traumatic brain injury and Alzheimer's disease, is the impairment of the blood-brain barrier (BBB), a critical structure for maintaining brain homeostasis. The compromised BBB in neurodegenerative conditions poses a significant challenge for effective treatment, as it allows harmful substances to accumulate in the brain. Nanomedicine offers a promising approach to overcoming this barrier, with nanoparticles (NPs) engineered to deliver therapeutic agents directly to affected brain regions. This review explores the classification and design of NPs, divided into organic and inorganic categories and further categorized based on their chemical and physical properties. These characteristics influence the ability of NPs to carry and release therapeutic agents, target specific tissues and ensure appropriate clearance from the body. The review emphasizes the potential of NPs to enhance the diagnosis and treatment of neurodegenerative diseases through targeted delivery, improved drug bioavailability and real-time therapeutic efficacy monitoring. By addressing the challenges of the compromised BBB and targeting inflammatory biomarkers, NPs represent a cutting-edge strategy in managing neurological disorders, promising better patient outcomes.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-28"},"PeriodicalIF":3.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142295997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
January 2024 industry update. 2024 年 1 月行业更新。
IF 4.2
Therapeutic delivery Pub Date : 2024-05-09 DOI: 10.1080/20415990.2024.2346045
Patrick Lim, Nebojsa Stilinovic, Armin Mooranian, Hani Al-Salami
{"title":"January 2024 industry update.","authors":"Patrick Lim, Nebojsa Stilinovic, Armin Mooranian, Hani Al-Salami","doi":"10.1080/20415990.2024.2346045","DOIUrl":"https://doi.org/10.1080/20415990.2024.2346045","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140899540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
January 2024 industry update. 2024 年 1 月行业更新。
IF 4.2
Therapeutic delivery Pub Date : 2024-05-09 DOI: 10.1080/20415990.2024.2346045
Patrick Lim, Nebojsa Stilinovic, Armin Mooranian, Hani Al-Salami
{"title":"January 2024 industry update.","authors":"Patrick Lim, Nebojsa Stilinovic, Armin Mooranian, Hani Al-Salami","doi":"10.1080/20415990.2024.2346045","DOIUrl":"https://doi.org/10.1080/20415990.2024.2346045","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-6"},"PeriodicalIF":4.2,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring contemporary breakthroughs in utilizing vesicular nanocarriers for breast cancer therapy. 探索利用囊泡纳米载体治疗乳腺癌的当代突破。
IF 4.2
Therapeutic delivery Pub Date : 2024-04-01 Epub Date: 2024-02-20 DOI: 10.4155/tde-2023-0092
Nalla Usha Kumari, Ekta Pardhi, Padakanti Sandeep Chary, Neelesh Kumar Mehra
{"title":"Exploring contemporary breakthroughs in utilizing vesicular nanocarriers for breast cancer therapy.","authors":"Nalla Usha Kumari, Ekta Pardhi, Padakanti Sandeep Chary, Neelesh Kumar Mehra","doi":"10.4155/tde-2023-0092","DOIUrl":"10.4155/tde-2023-0092","url":null,"abstract":"<p><p>Breast cancer (BC) is a heterogeneous disease with various morphological features, clinicopathological conditions and responses to different therapeutic options, which is responsible for high mortality and morbidity in women. The heterogeneity of BC necessitates new strategies for diagnosis and treatment, which is possible only by cautious harmonization of the advanced nanomaterials. Recent developments in vesicular nanocarrier therapy indicate a paradigm shift in breast cancer treatment by providing an integrated approach to address current issues. This review provides a detailed classification of various nanovesicles in the treatment of BC with a special emphasis on recent advances, challenges in translating nanomaterials and future potentials.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"279-303"},"PeriodicalIF":4.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139906512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring magnesium myristate for its dual functionality as a binder and lubricant in the formulation of tablet. 探索肉豆蔻酸镁在片剂配方中作为粘合剂和润滑剂的双重功能。
IF 4.2
Therapeutic delivery Pub Date : 2024-04-01 Epub Date: 2024-02-29 DOI: 10.4155/tde-2023-0101
Rachana Pockle, Rajashree Masareddy, Vijay Bambulkar, Rishabh Desai, Sai Kiran
{"title":"Exploring magnesium myristate for its dual functionality as a binder and lubricant in the formulation of tablet.","authors":"Rachana Pockle, Rajashree Masareddy, Vijay Bambulkar, Rishabh Desai, Sai Kiran","doi":"10.4155/tde-2023-0101","DOIUrl":"10.4155/tde-2023-0101","url":null,"abstract":"<p><p><b>Purpose:</b> To explore 'magnesium myristate' for its dual functionality as a lubricant and binder in the formulation of tablets. <b>Methods:</b> Using (DoE), tablet formulations using magnesium myristate and conventional excipients (magnesium stearate and PVP K30) were developed by wet granulation technique. The prepared granules and formulated tablets were evaluated for pre- and post-compression parameters, respectively. <b>Results:</b> Magnesium myristate exhibited excellent flow properties. The optimized formulations containing magnesium myristate exhibited increased hardness and <i>in vitro</i> drug release in comparison to conventional excipients. <i>f</i><sub>2</sub> similarity index for <i>in vitro</i> drug release showed no significant variations with optimized formulations and with the marketed formulations. <b>Conclusion:</b> Magnesium myristate shows a promising replacement for conventional excipients as both a lubricant and binder in tablet formulation.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"253-266"},"PeriodicalIF":4.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating anti-cancer activity of dual-loaded liposomes with thymoquinone and vitamin C. 研究胸腺醌和维生素 C 双载脂质体的抗癌活性
IF 4.2
Therapeutic delivery Pub Date : 2024-04-01 Epub Date: 2024-03-07 DOI: 10.4155/tde-2023-0140
Ahmed Munef, Zainab Lafi, Naeem Shalan
{"title":"Investigating anti-cancer activity of dual-loaded liposomes with thymoquinone and vitamin C.","authors":"Ahmed Munef, Zainab Lafi, Naeem Shalan","doi":"10.4155/tde-2023-0140","DOIUrl":"10.4155/tde-2023-0140","url":null,"abstract":"<p><p><b>Background:</b> Thymoquinone (TQ) and vitamin C (Vit C) have demonstrated individual anticancer effects in various studies. TQ exhibits inhibitory properties against tumor growth, induces apoptosis, while Vit C protects against DNA damage and oxidative stress. <b>Aim:</b> Formulation of TQ and Vit C combination into liposomes using two methods and investigate the synergistic anticancer. <b>Method:</b> Liposomal preparations were characterized, and the purity of drug components was confirmed using encapsulation efficiency (EE %). <b>Results:</b> <i>In vitro</i> cell viability studies demonstrated the inhibitory effect of TQ and Vit C against colorectal (HT29, 5.5 ± 0.9 μM) and lung cancer (A549, 6.25 ± 0.9 μM) cell lines with combination index <1. <b>Conclusion:</b> The formulation of TQ and Vit C displayed synergistic anticancer activity.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"267-278"},"PeriodicalIF":4.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140050454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are mathematical equations important for improving drug-delivery devices performances? 数学公式对提高给药装置的性能重要吗？
IF 4.2
Therapeutic delivery Pub Date : 2024-04-01 Epub Date: 2024-02-15 DOI: 10.4155/tde-2023-0125
Fabio Pizzetti, Giuseppe Perale, Maurizio Masi, Filippo Rossi
{"title":"Are mathematical equations important for improving drug-delivery devices performances?","authors":"Fabio Pizzetti, Giuseppe Perale, Maurizio Masi, Filippo Rossi","doi":"10.4155/tde-2023-0125","DOIUrl":"10.4155/tde-2023-0125","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"233-236"},"PeriodicalIF":4.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Probucol-bile acid based nanoparticles protect auditory cells from oxidative stress: an in vitro study. 基于丙三醇胆酸的纳米颗粒保护听觉细胞免受氧化应激：一项体外研究。
IF 4.2
Therapeutic delivery Pub Date : 2024-04-01 Epub Date: 2024-03-12 DOI: 10.4155/tde-2023-0099
Susbin Raj Wagle, Bozica Kovacevic, Corina Mihaela Ionescu, Thomas Foster, Melissa Jones, Momir Mikov, Andrew Wise, Armin Mooranian, Hani Al-Salami
{"title":"Probucol-bile acid based nanoparticles protect auditory cells from oxidative stress: an <i>in vitro</i> study.","authors":"Susbin Raj Wagle, Bozica Kovacevic, Corina Mihaela Ionescu, Thomas Foster, Melissa Jones, Momir Mikov, Andrew Wise, Armin Mooranian, Hani Al-Salami","doi":"10.4155/tde-2023-0099","DOIUrl":"10.4155/tde-2023-0099","url":null,"abstract":"<p><p><b>Aim:</b> Excessive free radicals contribute to oxidative stress and mitochondrial dysfunction in sensorineural hearing loss (SNHL). The antioxidant probucol holds promise, but its limited bioavailability and inner ear barriers hinder effective SNHL treatment. <b>Methodology:</b> We addressed this by developing probucol-loaded nanoparticles with polymers and lithocholic acid and tested them on House Ear Institute-Organ of Corti cells. <b>Results:</b> Probucol-based nanoparticles effectively reduced oxidative stress-induced apoptosis, enhanced cellular viability, improved probucol uptake and promoted mitochondrial function. Additionally, they demonstrated the capacity to reduce reactive oxygen species through the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway. <b>Conclusion:</b> This innovative nanoparticle system holds the potential to prevent oxidative stress-related hearing impairment, providing an effective solution for SNHL.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"237-252"},"PeriodicalIF":4.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信